Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com
What is the main difference between Ozempic and Mounjaro?
Ozempic and Mounjaro both lower blood sugar and lead to weight loss, but they don’t work through identical pathways. Ozempic’s active ingredient, semaglutide, targets a single hormone receptor called GLP-1. Mounjaro’s active ingredient, tirzepatide, targets two receptors, GLP-1 and GIP. That dual action is one of the main reasons patients often ask whether Mounjaro is simply a “stronger version” of Ozempic. It isn’t quite that simple, but the extra receptor does appear to make a measurable difference in trial results, which I’ll walk through below.
Both drugs are FDA approved for adults with type 2 diabetes, given as once-weekly injections alongside diet and exercise. Neither is officially approved as a standalone weight loss drug under these brand names; that role belongs to their sister products, Wegovy (semaglutide) and Zepbound (tirzepatide).
How do Ozempic and Mounjaro compare for blood sugar control?
Mounjaro has shown a larger average drop in A1C than Ozempic in head-to-head research. In the SURPASS-2 trial, published in The New England Journal of Medicine, researchers led by Frías and colleagues found that tirzepatide doses of 5 mg, 10 mg, and 15 mg reduced A1C by 2.01 to 2.30 percentage points, compared with a 1.86-point reduction for semaglutide at the 1 mg dose. That trial didn’t test Ozempic’s highest 2 mg dose, which was approved later, so the gap may narrow somewhat when compared against that dose.
For most of my patients, A1C matters less as a standalone number and more as a marker of long-term complication risk. Both drugs bring meaningful reductions, and either one, used consistently, can move a person out of poorly controlled diabetes territory within a few months.
Which drug produces more weight loss, Ozempic or Mounjaro?
When comparing Ozempic vs Mounjaro for weight loss results, Mounjaro tends to produce more weight loss on average. The same SURPASS-2 trial in The New England Journal of Medicine reported that tirzepatide led to nearly double the percentage of body weight lost compared with semaglutide 1 mg over 40 weeks. A separate head-to-head trial, SURMOUNT-5, also published in The New England Journal of Medicine, compared both drugs at their maximum tolerated doses over 72 weeks and found a mean weight change of negative 20.2 percent with tirzepatide versus negative 13.7 percent with semaglutide.
Real world data points in the same direction, though the exact numbers shift depending on the study population. A retrospective real-world study published in Advances in Therapy, using US pharmacy claims data on adults without type 2 diabetes, found that after one year of treatment, patients using tirzepatide lost an average of 16.5 percent of body weight compared with 14.1 percent for patients using semaglutide 2.4 mg.
Separately, a study published in the journal Obesity, led by researcher Gasoyan and colleagues, found that how long a person stays on treatment matters just as much as which drug they use. Patients who continued semaglutide or tirzepatide without discontinuing lost close to 12 percent of body weight at one year, compared with roughly 4 percent among those who stopped early, a reminder that consistency of use plays a major role in real world outcomes regardless of which GLP-1 medication is chosen.
None of this means Ozempic is a weak option. Losing even 10 percent of body weight brings real improvements in blood pressure, cholesterol, and joint strain. The dual-hormone mechanism in Mounjaro simply tends to push the average a bit further.
What are the side effects of each medication?
Both drugs share a similar side effect profile, largely gastrointestinal. Nausea, vomiting, diarrhea, constipation, and stomach discomfort are common with both, especially during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and worsening of diabetic eye disease. Neither should be used by anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, based on findings from animal studies.
The SURMOUNT-5 investigators, writing in The New England Journal of Medicine, noted that safety findings for both drugs were largely consistent with results seen when each medication was studied independently, meaning no new or unexpected safety signal emerged from comparing them directly. In practice, I’ve seen patients tolerate one drug better than the other for reasons that aren’t always predictable, which is part of why switching between them is sometimes considered.
Can you switch between Ozempic and Mounjaro?
Yes, switching is possible and reasonably common when side effects, cost, or treatment goals change. Because tirzepatide stays in the body for roughly 25 days and semaglutide for about 5 weeks, a prescriber will usually time the switch around when the previous drug has mostly cleared, particularly if the reason for switching was poor tolerance. There’s no officially established dose conversion between the two, since they work through different mechanisms, and any switch should be planned with your prescriber rather than done independently.
Which one is right for you?
If a larger average reduction in weight and A1C is the priority, Mounjaro often edges ahead in the data from The New England Journal of Medicine trials described above. If cardiovascular risk reduction is a bigger concern, Ozempic has FDA approval for lowering the risk of major cardiovascular events in people with type 2 diabetes and existing heart disease, an indication Mounjaro doesn’t currently carry, although research into that use is ongoing. Cost and insurance coverage also matter enormously in practice, as access can vary widely depending on the plan and whether the prescription is for diabetes or off label weight use. Some patients also prioritize convenience, long term adherence, or insurance coverage, which can influence the decision just as much as clinical data.
This is very much a conversation for your prescriber, who can weigh your A1C goals, weight goals, cardiovascular history, and tolerance for side effects together.
FAQs
Q1. Is Mounjaro stronger than Ozempic?
In head-to-head trial data published in The New England Journal of Medicine, Mounjaro has shown greater average weight loss and A1C reduction than Ozempic.
Q2. What is the main difference between how Ozempic and Mounjaro work?
Ozempic acts on one hormone receptor, GLP-1. Mounjaro acts on two, GLP-1 and GIP, which is thought to explain its slightly larger effect on appetite and blood sugar.
Q3. Can you switch between Ozempic and Mounjaro?
Yes, switching is done under medical supervision, usually timed around how long the previous drug remains active in the body.
Q4. How much weight can you lose on Mounjaro compared to Ozempic?
The SURMOUNT-5 trial found an average weight change of about 20 percent with tirzepatide versus about 14 percent with semaglutide at maximum doses over 72 weeks, though individual results vary widely.
Q5. Is Ozempic or Mounjaro better for someone with heart disease?
Ozempic carries FDA approval for reducing cardiovascular risk in people with type 2 diabetes and existing heart disease. Mounjaro does not currently have this indication.
Q6. Do Ozempic and Mounjaro have the same side effects?
Largely yes. Both commonly cause nausea, diarrhea, and stomach upset, and trial safety data has not shown major unexpected differences between them.
Q7. Which medication would you recommend, Ozempic or Mounjaro?
Neither is universally “better.” The right choice depends on your A1C goals, weight loss goals, cardiovascular history, cost, and how your body tolerates each one.
Before You Go
I know how overwhelming it can feel comparing injectable medications with so much conflicting information online. If you found this helpful, I’ve written in more depth on GLP-1 medications and metabolic health elsewhere on PharmaHealths.com, and I’d encourage you to explore those articles as you weigh your options. As always, bring your questions to your prescriber. They know your full health picture in a way no article can.
Disclaimer
This article is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult your doctor or pharmacist before starting, stopping, or switching any medication.
References
• The New England Journal of Medicine (SURPASS-2) — Head-to-head trial comparing tirzepatide vs semaglutide for A1C and weight loss
• The New England Journal of Medicine (SURMOUNT-5) — Long-term comparison of maximum-dose weight loss outcomes
• Advances in Therapy — Real-world US claims data on weight loss outcomes with tirzepatide vs semaglutide
• Obesity (journal) — Study highlighting the impact of treatment adherence on weight loss outcomes
